Overview of drugs approved by the FDA in 2022
The aim of the work is to conduct a review of medications approved by the FDA in 2022.Materials and methods. In searching for the materials to write this review article, bibliographic databases including PubMed, Google Scholar and e-library.ru were utilized. The search was conducted for the publicat...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2023-11-01
|
| Series: | Фармация и фармакология (Пятигорск) |
| Subjects: | |
| Online Access: | https://www.pharmpharm.ru/jour/article/view/1353 |
| _version_ | 1826559348121272320 |
|---|---|
| author | D. V. Kurkin E. I. Morkovin D. A. Bakulin Yu. V. Gorbunova Yu. A. Kolosov M. A. Dzhavakhyan I. E. Makarenko R. V. Drai A. V. Zaborovsky O. V. Shatalova A. V. Strygin V. I. Petrov A. P. Pleten A. A. Prokopov T. Yu. Tatarenko-Kozmina |
| author_facet | D. V. Kurkin E. I. Morkovin D. A. Bakulin Yu. V. Gorbunova Yu. A. Kolosov M. A. Dzhavakhyan I. E. Makarenko R. V. Drai A. V. Zaborovsky O. V. Shatalova A. V. Strygin V. I. Petrov A. P. Pleten A. A. Prokopov T. Yu. Tatarenko-Kozmina |
| author_sort | D. V. Kurkin |
| collection | DOAJ |
| description | The aim of the work is to conduct a review of medications approved by the FDA in 2022.Materials and methods. In searching for the materials to write this review article, bibliographic databases including PubMed, Google Scholar and e-library.ru were utilized. The search was conducted for the publications spanning the period from 2008 to 2023. Herewith, the following keywords and word combinations were used: new drug approval, NDA, drug authorization, approval package, breakthrough medicine.Results. The discovery and development of medications are among the most crucial scientific processes in healthcare. Developing a new drug is a highly intricate, expensive, and time-consuming process. Nowadays, the problem of costs reduction and the process of expedited discovering of new medications are particularly pertinent. To optimize the search for active compounds, virtual and high-throughput screenings, machine learning, artificial intelligence, cryo-electron microscopy, and drug repurposing are employed. Simultaneously, the search for original molecules to serve as the basis for innovative drugs continues. This article presents a review of medications approved by the FDA in 2022 for the treatment of various pathologies.Conclusion. A drug development is a complex and resource-intensive process, with only a small fraction of candidates advancing to clinical trials. A drug design evolves in tandem with societal needs, and this review highlights some of the medications approved by the FDA in 2022. Technological advancements are expected to expedite drug development, potentially reducing the time to the market. Biotechnology, including cell therapy, holds significant prospects, and achievements in genetic mapping and chip technologies will enhance the accessibility of personalized pharmacology. |
| first_indexed | 2025-02-18T20:40:57Z |
| format | Article |
| id | doaj.art-8583ca5a7d4043de9ab1b0dd5ccb0858 |
| institution | Directory Open Access Journal |
| issn | 2307-9266 2413-2241 |
| language | Russian |
| last_indexed | 2025-03-14T08:58:57Z |
| publishDate | 2023-11-01 |
| publisher | Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute |
| record_format | Article |
| series | Фармация и фармакология (Пятигорск) |
| spelling | doaj.art-8583ca5a7d4043de9ab1b0dd5ccb08582025-03-02T12:43:17ZrusVolgograd State Medical University, Pyatigorsk Medical and Pharmaceutical InstituteФармация и фармакология (Пятигорск)2307-92662413-22412023-11-0111319321010.19163/2307-9266-2023-11-3-193-210481Overview of drugs approved by the FDA in 2022D. V. Kurkin0E. I. Morkovin1D. A. Bakulin2Yu. V. Gorbunova3Yu. A. Kolosov4M. A. Dzhavakhyan5I. E. Makarenko6R. V. Drai7A. V. Zaborovsky8O. V. Shatalova9A. V. Strygin10V. I. Petrov11A. P. Pleten12A. A. Prokopov13T. Yu. Tatarenko-Kozmina141.Yevdokimov Moscow State University of Medicine and Dentistry. 2.Volgograd State Medical University.Volgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityYevdokimov Moscow State University of Medicine and Dentistry1.Yevdokimov Moscow State University of Medicine and Dentistry. 2.All-Russian Scientific Research Institute of Medicinal and Aromatic Plants.1.Yevdokimov Moscow State University of Medicine and Dentistry. 2.Farm-HoldingFarm-HoldingYevdokimov Moscow State University of Medicine and DentistryVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityYevdokimov Moscow State University of Medicine and DentistryYevdokimov Moscow State University of Medicine and DentistryYevdokimov Moscow State University of Medicine and DentistryThe aim of the work is to conduct a review of medications approved by the FDA in 2022.Materials and methods. In searching for the materials to write this review article, bibliographic databases including PubMed, Google Scholar and e-library.ru were utilized. The search was conducted for the publications spanning the period from 2008 to 2023. Herewith, the following keywords and word combinations were used: new drug approval, NDA, drug authorization, approval package, breakthrough medicine.Results. The discovery and development of medications are among the most crucial scientific processes in healthcare. Developing a new drug is a highly intricate, expensive, and time-consuming process. Nowadays, the problem of costs reduction and the process of expedited discovering of new medications are particularly pertinent. To optimize the search for active compounds, virtual and high-throughput screenings, machine learning, artificial intelligence, cryo-electron microscopy, and drug repurposing are employed. Simultaneously, the search for original molecules to serve as the basis for innovative drugs continues. This article presents a review of medications approved by the FDA in 2022 for the treatment of various pathologies.Conclusion. A drug development is a complex and resource-intensive process, with only a small fraction of candidates advancing to clinical trials. A drug design evolves in tandem with societal needs, and this review highlights some of the medications approved by the FDA in 2022. Technological advancements are expected to expedite drug development, potentially reducing the time to the market. Biotechnology, including cell therapy, holds significant prospects, and achievements in genetic mapping and chip technologies will enhance the accessibility of personalized pharmacology.https://www.pharmpharm.ru/jour/article/view/1353fdabiopharmaceuticalsmonoclonal antibodiesdrug design trends |
| spellingShingle | D. V. Kurkin E. I. Morkovin D. A. Bakulin Yu. V. Gorbunova Yu. A. Kolosov M. A. Dzhavakhyan I. E. Makarenko R. V. Drai A. V. Zaborovsky O. V. Shatalova A. V. Strygin V. I. Petrov A. P. Pleten A. A. Prokopov T. Yu. Tatarenko-Kozmina Overview of drugs approved by the FDA in 2022 Фармация и фармакология (Пятигорск) fda biopharmaceuticals monoclonal antibodies drug design trends |
| title | Overview of drugs approved by the FDA in 2022 |
| title_full | Overview of drugs approved by the FDA in 2022 |
| title_fullStr | Overview of drugs approved by the FDA in 2022 |
| title_full_unstemmed | Overview of drugs approved by the FDA in 2022 |
| title_short | Overview of drugs approved by the FDA in 2022 |
| title_sort | overview of drugs approved by the fda in 2022 |
| topic | fda biopharmaceuticals monoclonal antibodies drug design trends |
| url | https://www.pharmpharm.ru/jour/article/view/1353 |
| work_keys_str_mv | AT dvkurkin overviewofdrugsapprovedbythefdain2022 AT eimorkovin overviewofdrugsapprovedbythefdain2022 AT dabakulin overviewofdrugsapprovedbythefdain2022 AT yuvgorbunova overviewofdrugsapprovedbythefdain2022 AT yuakolosov overviewofdrugsapprovedbythefdain2022 AT madzhavakhyan overviewofdrugsapprovedbythefdain2022 AT iemakarenko overviewofdrugsapprovedbythefdain2022 AT rvdrai overviewofdrugsapprovedbythefdain2022 AT avzaborovsky overviewofdrugsapprovedbythefdain2022 AT ovshatalova overviewofdrugsapprovedbythefdain2022 AT avstrygin overviewofdrugsapprovedbythefdain2022 AT vipetrov overviewofdrugsapprovedbythefdain2022 AT appleten overviewofdrugsapprovedbythefdain2022 AT aaprokopov overviewofdrugsapprovedbythefdain2022 AT tyutatarenkokozmina overviewofdrugsapprovedbythefdain2022 |